(19)
(11) EP 4 561 621 A1

(12)

(43) Date of publication:
04.06.2025 Bulletin 2025/23

(21) Application number: 22789809.5

(22) Date of filing: 20.09.2022
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
A61P 37/02(2006.01)
A61P 21/04(2006.01)
C12N 15/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 37/02; A61P 21/04; C07K 16/2803; A61K 2039/505
(86) International application number:
PCT/US2022/076691
(87) International publication number:
WO 2024/025602 (01.02.2024 Gazette 2024/05)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 27.07.2022 US 202263369590 P

(71) Applicant: Viela Bio, Inc.
Deerfield, IL 60015 (US)

(72) Inventors:
  • REES, William
    Deerfield, Illinois 60015 (US)
  • SMITH, Michael
    Deerfield, Illinois 60015 (US)
  • KATZ, Eliezer
    Deerfield, Illinois 60015 (US)

(74) Representative: Lau, Sarah Jane et al
Kilburn & Strode LLP Lacon London 84 Theobalds Road
London WC1X 8NL
London WC1X 8NL (GB)

   


(54) INEBILIZUMAB AND METHODS OF USING THE SAME FOR SUSTAINED B-CELL DEPLETION